Global Osimertinib Generics 麻豆原创 Growth 2024-2030

Publication ID:

LPI11242373

Publication Date:

November 19, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Osimertinib generics refer to alternative versions of the drug osimertinib,which is used to treat non-small cell lung cancer (NSCLC) with EGFR mutations,including the T790M mutation.Generic osimertinib tablets contain the same active ingredient and are designed to have the same therapeutic effect as the branded version, inhibiting the EGFR tyrosine kinase to slow down or stop cancer cell growth.
The global Osimertinib Generics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淥simertinib Generics Industry Forecast鈥� looks at past sales and reviews total world Osimertinib Generics sales in 2023, providing a comprehensive analysis by region and market sector of projected Osimertinib Generics sales for 2024 through 2030. With Osimertinib Generics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osimertinib Generics industry.
This Insight Report provides a comprehensive analysis of the global Osimertinib Generics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osimertinib Generics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Osimertinib Generics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osimertinib Generics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osimertinib Generics.
United States market for Osimertinib Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Osimertinib Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Osimertinib Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Osimertinib Generics players cover Zydus, Wanbang Biopharmaceuticals, Drug International, Beacon, General Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Osimertinib Generics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
40mg per Tablet
80mg per Tablet
Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Zydus
Wanbang Biopharmaceuticals
Drug International
Beacon
General Pharmaceuticals
Pharmacil
Key Questions Addressed in this Report
What is the 10-year outlook for the global Osimertinib Generics market?
What factors are driving Osimertinib Generics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Osimertinib Generics market opportunities vary by end market size?
How does Osimertinib Generics break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Osimertinib Generics Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Osimertinib Generics by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Osimertinib Generics by Country/Region, 2019, 2023 & 2030
2.2 Osimertinib Generics Segment by Type
2.2.1 40mg per Tablet
2.2.2 80mg per Tablet
2.3 Osimertinib Generics Sales by Type
2.3.1 Global Osimertinib Generics Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Osimertinib Generics Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Osimertinib Generics Sale Price by Type (2019-2024)
2.4 Osimertinib Generics Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Osimertinib Generics Sales by Application
2.5.1 Global Osimertinib Generics Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Osimertinib Generics Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Osimertinib Generics Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Osimertinib Generics Breakdown Data by Company
3.1.1 Global Osimertinib Generics Annual Sales by Company (2019-2024)
3.1.2 Global Osimertinib Generics Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Osimertinib Generics Annual Revenue by Company (2019-2024)
3.2.1 Global Osimertinib Generics Revenue by Company (2019-2024)
3.2.2 Global Osimertinib Generics Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Osimertinib Generics Sale Price by Company
3.4 Key Manufacturers Osimertinib Generics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Osimertinib Generics Product Location Distribution
3.4.2 Players Osimertinib Generics Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Osimertinib Generics by Geographic Region
4.1 World Historic Osimertinib Generics 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Osimertinib Generics Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Osimertinib Generics Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Osimertinib Generics 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Osimertinib Generics Annual Sales by Country/Region (2019-2024)
4.2.2 Global Osimertinib Generics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Osimertinib Generics Sales Growth
4.4 APAC Osimertinib Generics Sales Growth
4.5 Europe Osimertinib Generics Sales Growth
4.6 Middle East & Africa Osimertinib Generics Sales Growth
5 Americas
5.1 Americas Osimertinib Generics Sales by Country
5.1.1 Americas Osimertinib Generics Sales by Country (2019-2024)
5.1.2 Americas Osimertinib Generics Revenue by Country (2019-2024)
5.2 Americas Osimertinib Generics Sales by Type (2019-2024)
5.3 Americas Osimertinib Generics Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Osimertinib Generics Sales by Region
6.1.1 APAC Osimertinib Generics Sales by Region (2019-2024)
6.1.2 APAC Osimertinib Generics Revenue by Region (2019-2024)
6.2 APAC Osimertinib Generics Sales by Type (2019-2024)
6.3 APAC Osimertinib Generics Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Osimertinib Generics by Country
7.1.1 Europe Osimertinib Generics Sales by Country (2019-2024)
7.1.2 Europe Osimertinib Generics Revenue by Country (2019-2024)
7.2 Europe Osimertinib Generics Sales by Type (2019-2024)
7.3 Europe Osimertinib Generics Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Osimertinib Generics by Country
8.1.1 Middle East & Africa Osimertinib Generics Sales by Country (2019-2024)
8.1.2 Middle East & Africa Osimertinib Generics Revenue by Country (2019-2024)
8.2 Middle East & Africa Osimertinib Generics Sales by Type (2019-2024)
8.3 Middle East & Africa Osimertinib Generics Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Osimertinib Generics
10.3 Manufacturing Process Analysis of Osimertinib Generics
10.4 Industry Chain Structure of Osimertinib Generics
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Osimertinib Generics Distributors
11.3 Osimertinib Generics Customer
12 World Forecast Review for Osimertinib Generics by Geographic Region
12.1 Global Osimertinib Generics 麻豆原创 Size Forecast by Region
12.1.1 Global Osimertinib Generics Forecast by Region (2025-2030)
12.1.2 Global Osimertinib Generics Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Osimertinib Generics Forecast by Type (2025-2030)
12.7 Global Osimertinib Generics Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Zydus
13.1.1 Zydus Company Information
13.1.2 Zydus Osimertinib Generics Product Portfolios and Specifications
13.1.3 Zydus Osimertinib Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Zydus Main Business Overview
13.1.5 Zydus Latest Developments
13.2 Wanbang Biopharmaceuticals
13.2.1 Wanbang Biopharmaceuticals Company Information
13.2.2 Wanbang Biopharmaceuticals Osimertinib Generics Product Portfolios and Specifications
13.2.3 Wanbang Biopharmaceuticals Osimertinib Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Wanbang Biopharmaceuticals Main Business Overview
13.2.5 Wanbang Biopharmaceuticals Latest Developments
13.3 Drug International
13.3.1 Drug International Company Information
13.3.2 Drug International Osimertinib Generics Product Portfolios and Specifications
13.3.3 Drug International Osimertinib Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Drug International Main Business Overview
13.3.5 Drug International Latest Developments
13.4 Beacon
13.4.1 Beacon Company Information
13.4.2 Beacon Osimertinib Generics Product Portfolios and Specifications
13.4.3 Beacon Osimertinib Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Beacon Main Business Overview
13.4.5 Beacon Latest Developments
13.5 General Pharmaceuticals
13.5.1 General Pharmaceuticals Company Information
13.5.2 General Pharmaceuticals Osimertinib Generics Product Portfolios and Specifications
13.5.3 General Pharmaceuticals Osimertinib Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 General Pharmaceuticals Main Business Overview
13.5.5 General Pharmaceuticals Latest Developments
13.6 Pharmacil
13.6.1 Pharmacil Company Information
13.6.2 Pharmacil Osimertinib Generics Product Portfolios and Specifications
13.6.3 Pharmacil Osimertinib Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Pharmacil Main Business Overview
13.6.5 Pharmacil Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.